Prestige Consumer Healthcare Inc.

Good day and thank you for standing by. Welcome to the Prestige Consumer Health Care's fourth quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Phil Terpily, Vice President, Investor Relations and Treasury. Please go ahead.

Thanks, Operator, and thank you to everyone who has joined today. On the call with me are Ron Lombardi, our Chairman, President, and CEO, and Christine Sacco, our CFO and COO. On today's call, we'll review our full year fiscal 2025 results, discuss our full year outlook, and then take questions from analysts. A slide presentation accompanies today's call. It can be accessed by visiting PrestigeConsumerHealthcare.com, clicking on the Investors link, and then on today's webcast and presentation. Remember, some of the information contained in the presentation today includes non-GAAP financial measures. Reconciliations to the nearest GAAP financial measures are included in our earnings release and slide presentation. On today's call, management will make forward-looking statements around risks and uncertainties. They're detailed in a complete safe harbor disclosure on page two of the slide presentation, which accompanies the call. These are important to review and contemplate. Business environment uncertainty remains heightened due to evolving U.S. and international tariffs, supply chain constraints, and inflation, which have numerous potential impacts. This means results could change at any time, and the forecasted impact of risk considerations is a best estimate based on the information available as of today's date. Additional information concerning risk factors and cautionary statements are available in our most recent SEC filings and our most recent company 10-K. I'll now hand it over to our CEO, Ron Lombardi. Ron? Thanks, Phil.

Let's begin on slide five. We are very pleased with our record fiscal 25 results which delivered a year of solid revenue and earnings growth, thanks to our diversified portfolio of brands and proven business attributes. Net revenue of over $1.1 billion increased just over 1% versus the prior year, consistent with our forecast. Our international segment growth continues to deliver growth in excess of 5%, while in North America, many of our GI brands, such as Dramamine and Fleet, continue to experience superior results. We've also continued to see stabilization for the Summer's Eve brand within the women's health category, which was a key priority we discussed at the start of the year. For profitability, we expanded gross margins slightly, anticipate further expansion in fiscal 26, which Chris will discuss later. This helped generate solid adjusted EPS of $4.52, up approximately 7%, consistent to our long-term growth objective. We continued to execute a steady and disciplined capital allocation strategy using our strong fiscal 25 free cash flow, which was in excess of $240 million. to finish the year at 2.4 times leverage while still executing value-enhancing capital deployment. Chris will review our go-forward capital allocation priorities later. Now with that, let's turn to the next section for a reminder of a few of the ways our unique business strategy looks to generate consistent long-term performance. To begin, slide seven is a reminder of our marketing agility. One of the benefits of having a wide-ranging portfolio of brands is the ability to adjust our brand-building strategy and allocations in real time, focusing investments around the best near-term opportunities wherever they arise. In fiscal 25, we faced supply challenges for ClearEyes, which we discussed last May. We worked quickly to refocus marketing efforts around the rest of our eye and ear care portfolio, TheraTears, Dbrox, and Stye, each of which had unique opportunities available to invest behind. For TheraTears, we leveraged its well-recognized heritage of the dry ice solution in multiple ways to generate solid growth of approximately 10%. For Stye and Dbrox, two brands synonymous with their categories, a combination of innovation and accelerated marketing investments helped add incremental growth. The result was clear. As shown on the left of the slide, these three brands outperformed their combined category growth by over three percentage points and are well positioned for continued growth. This agility in investments is a unique strength of our business and we will continuously look to pivot into the best marketing opportunities that drive superior revenue growth. Now, let's turn to slide eight to discuss the e-commerce channel. Beyond executing successful marketing, we are focused on aligning our investments into channels that are important to consumers. We continue to see consumers shift channels, most prominently toward e-commerce, where our long-term investments have enabled continued success. Even with robust growth over the last five years, we continue to maintain a consistent double-digit sales growth profile. For fiscal 25, we experienced solid consumption growth with strong performance across our key partners, thanks to multiple tactics and solid retail partnerships. Each of our individual brands develops and maintains its own e-commerce strategy, including continuous improvements to the user experience to help retain loyal consumers. For example, our recent refresh of the STI website helps consumers educate themselves around STI symptoms and relief options. Equally important is engaging content that can help drive traffic and conversion of new users. We've had wide-ranging success across our portfolio with some examples shown on the right side of the page. So we reviewed both marketing and channel opportunities Now let's turn to slide nine to discuss innovation. Innovation continues to be a key part of Prestige's brand building toolkit. We operate with a multi-year pipeline of new product development concepts to ensure we generate new SKUs that match the needs of consumers. As shown on the page, the tactical elements to success for the various products launched in fiscal 26 are wide ranging. Most importantly, All of our innovation seeks to provide better consumer experiences. Each is designed to satisfy key consumer interests, like launching a new flavor, adding of an efficacious ingredient, or a new claim. Some of the latest product highlights these attributes include the recent launch of watermelon and pineapple flavors for Hydrolyte, as well as the Monistat Maintain Kit, which contains boric acid in two formats in an all-in-one odor solution. designed for pH balance while addressing odor and discharge. Incrementally, some innovations often seek to build on improving consumer experience through new technologies or form factors. An example of this we've discussed in the past was the launch of Compound W NitroFreeze, a work treatment solution with extreme freezing technology not available in other OTC treatments. For fiscal 26, we have numerous new form factors across multiple products, including the launch of Summer's Eve Whole Body Deodorant and the recent launch of Fleet's Oral Stool Softener. Lastly, many of our product launches help expand our brands into adjacent categories, leveraging their history of efficacy and strong brand heritage with consumers. One recent example is Goodies Plus Headache Pain and Mental Alertness. which takes Goody's proven history of fast pain relief combined with added caffeine to help consumers get back to the things they enjoy faster. So in summary, we have a long history of innovation, another great year planned for 26, and a continuous new product pipeline that should help drive consistent organic sales growth over time. With that, I'll turn it to Chris to discuss the financials.